Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 3
2017 2
2018 6
2019 2
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
[What is new in the management of multiple myeloma].
Vrancken L, Muller J, Lejeune M, Gregoire C, Delens L, Jaspers A, Servais S, Prijck B, Baron F, Caers J, Beguin Y. Vrancken L, et al. Among authors: muller j. Rev Med Suisse. 2018 Aug 22;14(615):1438-1442. Rev Med Suisse. 2018. PMID: 30136458 French.
Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease.
Fransolet G, Ehx G, Somja J, Delens L, Hannon M, Muller J, Dubois S, Drion P, Caers J, Humblet-Baron S, Delvenne P, Beguin Y, Conteduca G, Baron F. Fransolet G, et al. Among authors: muller j. J Hematol Oncol. 2016 Jul 4;9(1):53. doi: 10.1186/s13045-016-0281-2. J Hematol Oncol. 2016. PMID: 27377819 Free PMC article.
Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice.
Ehx G, Somja J, Warnatz HJ, Ritacco C, Hannon M, Delens L, Fransolet G, Delvenne P, Muller J, Beguin Y, Lehrach H, Belle L, Humblet-Baron S, Baron F. Ehx G, et al. Among authors: muller j. Front Immunol. 2018 Aug 30;9:1943. doi: 10.3389/fimmu.2018.01943. eCollection 2018. Front Immunol. 2018. PMID: 30214443 Free PMC article.
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease.
Muller J, Bolomsky A, Dubois S, Duray E, Stangelberger K, Plougonven E, Lejeune M, Léonard A, Marty C, Hempel U, Baron F, Beguin Y, Cohen-Solal M, Ludwig H, Heusschen R, Caers J. Muller J, et al. Haematologica. 2018 Aug;103(8):1359-1368. doi: 10.3324/haematol.2017.185397. Epub 2018 May 10. Haematologica. 2018. PMID: 29748441 Free PMC article.
The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene.
Bolomsky A, Muller J, Stangelberger K, Lejeune M, Duray E, Breid H, Vrancken L, Pfeiffer C, Hübl W, Willheim M, Weetall M, Branstrom A, Zojer N, Caers J, Ludwig H. Bolomsky A, et al. Among authors: muller j. Br J Haematol. 2020 Sep;190(6):877-890. doi: 10.1111/bjh.16595. Epub 2020 Mar 30. Br J Haematol. 2020. PMID: 32232850 Free article.
12 results